Lonza has launched the PyroCell Monocyte Activation Test System, a sustainable and reliable solution for in vitro pyrogen testing. The new offering expands Lonza’s primary cells and endotoxin testing, combined with Sanquin’s expertise in MAT production, to help ensure the safety of parenteral pharmaceuticals during development, manufacture and product release.



The PyroCell MAT System is designed to improve upon existing methods for pyrogen detection in complex formulations, such as human vaccines and cell-based biologics. It provides sensitive pyrogen detection without the use of experimental animals, thereby supporting sustainability objectives.

Through a collaboration with Sanquin Reagents, Lonza’s PyroCell MAT System is comprised of pooled, cryopreserved Peripheral Blood Mononuclear Cells (PBMCs) specifically developed for use with the MAT. These cryopreserved PyroCell Kit PBMCs eliminate the need to qualify blood donors and undertake cell isolation for each single test run. With the PyroCell MAT System, the cells can be available on demand as needed.

The PyroCell MAT System reagents can now be purchased throughout North America and Europe through Lonza’s comprehensive distribution network and sales support services.